Quantbot Technologies LP Acquires Shares of 101,543 Bausch Health Companies Inc. (NYSE:BHC)

Quantbot Technologies LP bought a new position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 101,543 shares of the company's stock, valued at approximately $829,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Bausch Health Companies by 1.0% during the first quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company's stock worth $124,285,000 after buying an additional 114,862 shares during the period. Bank of Montreal Can lifted its holdings in shares of Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company's stock worth $31,598,000 after acquiring an additional 2,685,675 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Bausch Health Companies by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company's stock worth $22,063,000 after buying an additional 341,936 shares during the period. Mackenzie Financial Corp grew its holdings in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock worth $16,612,000 after purchasing an additional 1,252,834 shares during the period. Finally, Private Management Group Inc. raised its stake in shares of Bausch Health Companies by 43.0% in the 2nd quarter. Private Management Group Inc. now owns 1,495,953 shares of the company's stock valued at $10,427,000 after acquiring an additional 449,623 shares during the period. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Companies Price Performance

Shares of NYSE BHC traded down $0.45 during mid-day trading on Monday, hitting $7.92. The company's stock had a trading volume of 1,179,377 shares, compared to its average volume of 2,829,635. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $11.46. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -17.44 and a beta of 0.74. The company's fifty day simple moving average is $8.41 and its 200-day simple moving average is $7.14.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion during the quarter, compared to analysts' expectations of $2.42 billion. During the same period last year, the business earned $1.03 EPS. The business's quarterly revenue was up 12.2% on a year-over-year basis. On average, sell-side analysts predict that Bausch Health Companies Inc. will post 3.74 EPS for the current year.

Insider Transactions at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the transaction, the executive vice president now directly owns 435,198 shares in the company, valued at approximately $2,702,579.58. This represents a 2.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.12% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BHC shares. Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a research report on Friday, November 1st. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Friday, October 25th. Jefferies Financial Group dropped their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, August 7th. Finally, Evercore ISI raised shares of Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Bausch Health Companies presently has a consensus rating of "Hold" and a consensus price target of $7.75.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.